📋 Pep IQ provides independent reference information for educational purposes only. Nothing here constitutes medical advice or treatment recommendation. All compounds require individual assessment. Consult a qualified physician before considering any peptide protocol.
Melanocortin MC3R/MC4R Agonist Cyclic Heptapeptide

Bremelanotide

PT-141 · Vyleesi · Cyclic Melanocortin Heptapeptide

"The only FDA-approved treatment for sexual desire that works in the brain, not the blood vessels. Unlike Viagra, it doesn't move blood — it moves desire. The distinction matters enormously for the people it helps most."

Type
Cyclic heptapeptide · α-MSH derivative
Mechanism
Central MC3R/MC4R agonist · dopamine pathway
Status
UK: prescription only medicine · WADA: not specifically listed · US FDA: approved 2019 as Vyleesi for HSDD in premenopausal women
Route
SubQ autoinjector · ~45 min before activity
Protocol summary
FDA dose
1.75 mg SubQ on demand
Timing
~45 min before activity
Frequency
Max 1/24h · 8 doses/month
Clinical-labelled
1.75 mg SubQ ~45 min pre-activity · max 1/24h · max 8/month
Contraindicated in uncontrolled hypertension or cardiovascular disease; transient BP rises documented
How we read the evidence
FDA-approved (Vyleesi) · two Phase 3 RCTs · the most clinically validated peptide for sexual function
Animal evidence

Melanocortin receptor activation in animal models established the central nervous system mechanism for sexual desire and arousal — preclinical work focused on hypothalamic MC4R activation rather than peripheral effects. Animal data supported the trial designs but human evidence is now where this compound's case sits.

Community & clinical practice

Community use closely follows the FDA protocol: 1.75 mg SubQ ~45 minutes before anticipated sexual activity, maximum once per 24 hours, no more than 8 doses per month. Some users start with 1 mg to test nausea tolerance before moving to the standard 1.75 mg. Off-label use in men with ED at the same dose is reported with meaningful response rates; combination with low-dose sildenafil (25 mg) is described in some andrology clinics for PDE5-resistant patients. Daily continuous dosing is not how this peptide is used — receptor saturation and cumulative side effects (notably hyperpigmentation) build with frequency.

Human trial data

Two Phase 3 RECONNECT trials enrolled over 1,200 women with hypoactive sexual desire disorder (HSDD), randomised double-blind placebo-controlled. Results led to FDA approval (June 2019) as Vyleesi. Phase 2 dose-finding identified 1.75 mg as optimal: lower doses (0.75 mg, 1.25 mg) showed less consistent efficacy. Pre-marketing intranasal trials in male erectile dysfunction reported 34% achieving erection sufficient for intercourse vs 9% placebo, but the intranasal program was halted by the FDA in 2007 due to blood pressure concerns; injectable formulation continued.

Regulatory status

FDA-approved (Vyleesi, 2019) for premenopausal women with HSDD. Off-label use in men is not FDA-approved. Contraindicated in uncontrolled hypertension and cardiovascular disease — transient BP rises are documented. Naltrexone interaction (reduces naltrexone efficacy) is on the label.

Convergence

Bremelanotide is one of the very few peptides with full FDA approval and a robust Phase 3 evidence base. Standard protocol is the FDA dose: 1.75 mg SubQ as needed, 45 min before activity, max 1 dose/24h and 8 doses/month. The hard ceiling is real — stacking does not increase effect, only side effects. Side effects (~40% nausea, transient BP rise, possible focal hyperpigmentation) are well characterised. For the right patient with HSDD or PDE5-resistant ED, this is one of the most clinically validated peptides available.

Origin & Background

From tanning peptide to desire drug

Bremelanotide began its life as a derivative of Melanotan II — a peptide originally developed to stimulate skin tanning through melanocortin receptor activation. Researchers at the University of Arizona noticed something unexpected in early Melanotan II trials: male subjects were reporting spontaneous erections. This accidental observation redirected the research programme toward sexual dysfunction.

The active compound was refined into PT-141 (bremelanotide), a cyclic heptapeptide that selectively activates melanocortin receptors MC3R and MC4R in the hypothalamus and limbic system. In June 2019, the FDA approved it under the brand name Vyleesi for the treatment of acquired, generalised hypoactive sexual desire disorder (HSDD) in premenopausal women — making it the first and only centrally-acting approved treatment for low sexual desire.

The approval was based on the RECONNECT Phase III trials (n=1,247) which demonstrated statistically significant increases in satisfying sexual events and significant reductions in distress related to low desire. The clinical effect was modest but real — the FDA advisory committee voted 14–2 in favour of approval, recognising the unmet need and the unique central mechanism.

Why the mechanism matters: PDE5 inhibitors (Viagra, Cialis) work by preventing blood from leaving the penis — they require sexual stimulation and work on vessels. PT-141 activates desire pathways in the brain directly — it works regardless of vascular function and in people who already have adequate blood flow but lack desire. They address completely different aspects of sexual function.

Science & Mechanism

The brain's desire circuit

Mechanism of Action

1
MC3R/MC4R activation: Bremelanotide binds to melanocortin-3 and melanocortin-4 receptors in the hypothalamus and limbic system — brain regions governing desire, motivation and reward. This is centrally mediated, not peripheral.
2
Dopaminergic pathway activation: MC4R agonism in the medial preoptic area and ventral tegmental region activates dopaminergic pathways associated with sexual motivation and reward. Dopamine increases make social and sexual stimuli more salient and rewarding.
3
Desire vs. performance: The result is enhanced sexual desire and arousal — the wanting component — rather than mechanical performance enhancement. This is why it is described as a desire drug rather than an erectile drug, even though some erectile response occurs as a downstream effect in men.
4
Onset and duration: Peak plasma concentration reached in approximately 1 hour after SubQ injection. Sexual effects typically begin within 45–90 minutes. Duration of action approximately 8–12 hours. No next-day effects reported.
5
Melanin side effect: MC1R activation (an off-target receptor) stimulates melanin production — leading to the characteristic skin hyperpigmentation seen with repeated use, particularly in darker skin types.

The RECONNECT trials established modest but statistically significant efficacy in women with HSDD: approximately 0.5 additional satisfying sexual events per month versus placebo, alongside significant improvement in desire scores and reduction in sexual distress. The modest effect size reflects the complexity of HSDD — it is multifactorial and PT-141 addresses only the biological component.

For men, the data is more limited but intriguing. A study of 342 ED patients who were non-responsive to sildenafil found that 34% of the bremelanotide group reported significant improvement versus 9% placebo — particularly notable given these were PDE5i non-responders for whom no other options existed. A 2024 observational study of 21 men reported 80% satisfaction, 52% improvement in ED, and 39% improvement in desire.

Benefits & Evidence

What the data shows

💕
Sexual desire restoration in women (HSDD)
RECONNECT Phase III (n=1,247) showed statistically significant increases in satisfying sexual events and sexual desire scores, alongside significant reduction in FSDD distress scores. FDA advisory committee voted 14–2 for approval. Modest but clinically meaningful effect.
● Strong — Phase III RCT · FDA approved
⚡
Erectile response in men — including PDE5i non-responders
34% vs 9% placebo response in sildenafil non-responders (Safarinejad & Hosseini, 2008). Phase I data showed significant base rigidity improvement at 10–20mg doses. Combination with low-dose sildenafil (25mg) produced significantly greater response than sildenafil alone. Not FDA-approved for this indication.
● Moderate — Phase II data, off-label
🧠
Desire enhancement in men (low libido)
2024 observational study (Goldstein & Goldstein, 21 men): 39% reported improvement in sexual desire, 80% satisfied overall, 86% felt more confident initiating intimacy. Central mechanism targets desire directly regardless of testosterone status.
● Limited — small observational study
💊
SSRI-induced sexual dysfunction
SSRIs commonly cause reduced desire — the domain PT-141 directly targets. The RECONNECT trials excluded this population so direct evidence is limited, but clinicians report this as one of the most promising off-label applications given the mechanistic alignment. Emerging clinical use.
● Emerging — mechanistic rationale, limited trial data
Things to know

Risks & considerations

⚠️
Well-characterised but notable side effects. Bremelanotide is the best-studied peptide for sexual dysfunction — Phase III safety data from 1,247 subjects exists. Nausea is common and transient. Blood pressure elevation is real but small. Hyperpigmentation is the most concerning long-term risk with frequent use.
Moderate
Nausea — the most common side effect, occurring in approximately 40% of users. Usually mild and transient, peaking 30–60 minutes post-injection. Significantly reduced by eating a light meal 2 hours before injection and/or taking ondansetron (Zofran) 30 minutes prior.
Mild
Flushing and headache — brief, transient, mild to moderate intensity. Very common in first few uses. Usually diminishes with repeated administration.
Moderate
Transient blood pressure increase — mean increase of approximately 2mmHg systolic and diastolic, peaking 4–8 hours post-dose. Clinically insignificant in healthy individuals but potentially significant in those with hypertension or cardiovascular disease.
Moderate
Hyperpigmentation — MC1R off-target activation stimulates melanin production. Can cause darkening of the face, breasts, gums and areas of existing pigmentation. More common with frequent dosing. Rare but reported. Generally reversible on cessation.
Serious
Contraindicated in cardiovascular disease — the blood pressure elevation, even if modest, means bremelanotide is not recommended in patients with cardiovascular conditions. Combined use with alcohol requires caution due to cardiovascular effects of both.

⚠ Key Warnings

Maximum one dose per 24 hours, maximum 8 doses per month as per FDA labelling. Exceeding frequency increases hyperpigmentation and cardiovascular risk.
Not for use in people with uncontrolled hypertension or cardiovascular disease.
Compounded intranasal PT-141 is not FDA-approved and has different pharmacokinetics and dose requirements than the approved Vyleesi autoinjector. The two are not interchangeable.
Not FDA-approved for use in men — off-label prescribing is a physician's decision and requires informed consent.
Not currently on the WADA prohibited list, but melanocortin agonists may face future scrutiny.